These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

637 related items for PubMed ID: 26152357

  • 1. Platelet-Synthesized Testosterone in Men with Prostate Cancer Induces Androgen Receptor Signaling.
    Zaslavsky AB, Gloeckner-Kalousek A, Adams M, Putluri N, Venghatakrishnan H, Li H, Morgan TM, Feng FY, Tewari M, Sreekumar A, Palapattu GS.
    Neoplasia; 2015 Jun; 17(6):490-6. PubMed ID: 26152357
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
    Shafi AA, Yen AE, Weigel NL.
    Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
    [Abstract] [Full Text] [Related]

  • 4. Resistance to docetaxel in prostate cancer is associated with androgen receptor activation and loss of KDM5D expression.
    Komura K, Jeong SH, Hinohara K, Qu F, Wang X, Hiraki M, Azuma H, Lee GS, Kantoff PW, Sweeney CJ.
    Proc Natl Acad Sci U S A; 2016 May 31; 113(22):6259-64. PubMed ID: 27185910
    [Abstract] [Full Text] [Related]

  • 5. Androgen receptor co-regulatory networks in castration-resistant prostate cancer.
    Sung YY, Cheung E.
    Endocr Relat Cancer; 2014 Feb 31; 21(1):R1-R11. PubMed ID: 24152433
    [Abstract] [Full Text] [Related]

  • 6. Identification of an anabolic selective androgen receptor modulator that actively induces death of androgen-independent prostate cancer cells.
    Schmidt A, Meissner RS, Gentile MA, Chisamore MJ, Opas EE, Scafonas A, Cusick TE, Gambone C, Pennypacker B, Hodor P, Perkins JJ, Bai C, Ferraro D, Bettoun DJ, Wilkinson HA, Alves SE, Flores O, Ray WJ.
    J Steroid Biochem Mol Biol; 2014 Sep 31; 143():29-39. PubMed ID: 24565564
    [Abstract] [Full Text] [Related]

  • 7. Testosterone boosts for treatment of castration resistant prostate cancer: an experimental implementation of intermittent androgen deprivation.
    Thelen P, Heinrich E, Bremmer F, Trojan L, Strauss A.
    Prostate; 2013 Nov 31; 73(15):1699-709. PubMed ID: 23868789
    [Abstract] [Full Text] [Related]

  • 8. Differential regulation of metabolic pathways by androgen receptor (AR) and its constitutively active splice variant, AR-V7, in prostate cancer cells.
    Shafi AA, Putluri V, Arnold JM, Tsouko E, Maity S, Roberts JM, Coarfa C, Frigo DE, Putluri N, Sreekumar A, Weigel NL.
    Oncotarget; 2015 Oct 13; 6(31):31997-2012. PubMed ID: 26378018
    [Abstract] [Full Text] [Related]

  • 9. Intracrine androgen biosynthesis in renal cell carcinoma.
    Lee GT, Han CS, Kwon YS, Patel R, Modi PK, Kwon SJ, Faiena I, Patel N, Singer EA, Ahn HJ, Kim WJ, Kim IY.
    Br J Cancer; 2017 Mar 28; 116(7):937-943. PubMed ID: 28253524
    [Abstract] [Full Text] [Related]

  • 10. Targeting GPR30 with G-1: a new therapeutic target for castration-resistant prostate cancer.
    Lam HM, Ouyang B, Chen J, Ying J, Wang J, Wu CL, Jia L, Medvedovic M, Vessella RL, Ho SM.
    Endocr Relat Cancer; 2014 Mar 28; 21(6):903-14. PubMed ID: 25287069
    [Abstract] [Full Text] [Related]

  • 11. Transcript Levels of Androgen Receptor Variant 7 and Ubiquitin-Conjugating Enzyme 2C in Hormone Sensitive Prostate Cancer and Castration-Resistant Prostate Cancer.
    Lee CH, Ku JY, Ha JM, Bae SS, Lee JZ, Kim CS, Ha HK.
    Prostate; 2017 Jan 28; 77(1):60-71. PubMed ID: 27550197
    [Abstract] [Full Text] [Related]

  • 12. Co-targeting AR and HSP90 suppresses prostate cancer cell growth and prevents resistance mechanisms.
    Centenera MM, Carter SL, Gillis JL, Marrocco-Tallarigo DL, Grose RH, Tilley WD, Butler LM.
    Endocr Relat Cancer; 2015 Oct 28; 22(5):805-18. PubMed ID: 26187127
    [Abstract] [Full Text] [Related]

  • 13. Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: Opportunities for therapeutic targeting from multiple angles.
    Hoang DT, Iczkowski KA, Kilari D, See W, Nevalainen MT.
    Oncotarget; 2017 Jan 10; 8(2):3724-3745. PubMed ID: 27741508
    [Abstract] [Full Text] [Related]

  • 14. Paracrine sonic hedgehog signaling contributes significantly to acquired steroidogenesis in the prostate tumor microenvironment.
    Lubik AA, Nouri M, Truong S, Ghaffari M, Adomat HH, Corey E, Cox ME, Li N, Guns ES, Yenki P, Pham S, Buttyan R.
    Int J Cancer; 2017 Jan 15; 140(2):358-369. PubMed ID: 27672740
    [Abstract] [Full Text] [Related]

  • 15. Low β₂-adrenergic receptor level may promote development of castration resistant prostate cancer and altered steroid metabolism.
    Braadland PR, Grytli HH, Ramberg H, Katz B, Kellman R, Gauthier-Landry L, Fazli L, Krobert KA, Wang W, Levy FO, Bjartell A, Berge V, Rennie PS, Mellgren G, Mælandsmo GM, Svindland A, Barbier O, Taskén KA.
    Oncotarget; 2016 Jan 12; 7(2):1878-94. PubMed ID: 26646591
    [Abstract] [Full Text] [Related]

  • 16. Stromal androgen receptor regulates the composition of the microenvironment to influence prostate cancer outcome.
    Leach DA, Need EF, Toivanen R, Trotta AP, Palethorpe HM, Tamblyn DJ, Kopsaftis T, England GM, Smith E, Drew PA, Pinnock CB, Lee P, Holst J, Risbridger GP, Chopra S, DeFranco DB, Taylor RA, Buchanan G.
    Oncotarget; 2015 Jun 30; 6(18):16135-50. PubMed ID: 25965833
    [Abstract] [Full Text] [Related]

  • 17. The NLR-related protein NWD1 is associated with prostate cancer and modulates androgen receptor signaling.
    Correa RG, Krajewska M, Ware CF, Gerlic M, Reed JC.
    Oncotarget; 2014 Mar 30; 5(6):1666-82. PubMed ID: 24681825
    [Abstract] [Full Text] [Related]

  • 18. Concurrent Androgen and Estrogen Ablation and Inhibition of Steroid Biosynthetic Enzyme Treatment for Castration-resistant Prostate Cancer.
    Sinha AA, Pomroy FE, Wilson MJ.
    Anticancer Res; 2016 Aug 30; 36(8):3847-54. PubMed ID: 27466486
    [Abstract] [Full Text] [Related]

  • 19. Pomegranate extracts impact the androgen biosynthesis pathways in prostate cancer models in vitro and in vivo.
    Ming DS, Pham S, Deb S, Chin MY, Kharmate G, Adomat H, Beheshti EH, Locke J, Guns ET.
    J Steroid Biochem Mol Biol; 2014 Sep 30; 143():19-28. PubMed ID: 24565566
    [Abstract] [Full Text] [Related]

  • 20. Orphan nuclear receptor TLX contributes to androgen insensitivity in castration-resistant prostate cancer via its repression of androgen receptor transcription.
    Jia L, Wu D, Wang Y, You W, Wang Z, Xiao L, Cai G, Xu Z, Zou C, Wang F, Teoh JY, Ng CF, Yu S, Chan FL.
    Oncogene; 2018 Jun 30; 37(25):3340-3355. PubMed ID: 29555975
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.